ONE WORLD CANNABIS
Israeli-based Leading Edge
Cannabis Research
OWC Pharmaceutical Research Corp. (OTCQB:OWCP)
is engaged in the business, through
its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., of
conducting medical research and
clinical trials, in full compliance with
all international regulatory protocols, for the development of cannabis-based products and treatments
specifically designed for multiple
myeloma, psoriasis, fibromyalgia,
PTSD, migraines, and of a unique
delivery system.
One World Cannabis Ltd., is focused
on discovering, developing and
commercializing cannabis-based
novel therapeutics products and
treatments specifically designed for
several medical conditions, starting
with multiple myeloma, psoriasis,
fibromyalgia, PTSD (post-traumatic
stress disorder) and migraines.
One World Cannabis is a young
company that, despite its youth,
is already playing a part in making
history.
CANNAINVESTOR Magazine
The expert team delivers years of
proven practices in diverse disciplines, including medical science
and regulatory affairs, as well as
extensive cannabis-related issues
experience.
One World Cannabis aspires to
become one of the world’s leading
players in the hyper-growing market of medical cannabis by providing the missing yet prerequisite
element of scientific validity for
cannabis based products.
The Company is committed to and
the highest standards of integrity
and ethics in proposing, conducting and reporting research. All its
investigations and researches are
conducted at the facilities of leading
Israeli medical centers, as well as at
the labs of the R&D pharmaceutical companies we contracted with.
The Company adheres to all the
necessary regulatory requirements,
including submitting its research
protocols to Ethics Committee (IRB)
approval.